9MW 2821
Alternative Names: 9MW-2821Latest Information Update: 17 Jul 2024
At a glance
- Originator Mabwell (Shanghai) Bioscience
- Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Urogenital cancer
- Phase I/II Solid tumours
Most Recent Events
- 15 Jul 2024 NMPA approves clinical trial application of 9MW 2821 in triple-negative breast cancer
- 15 Jul 2024 Mabwell plans a phase II trial for Triple negative breast cancer (Metastatic disease, Late stage disease, Monotherapy, Combination therapy) (IV, Infusion) in July 2024
- 01 Jul 2024 9MW 2821 receives fast track status for Triple-negative breast cancer in USA